Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.

Florian Huemer,Verena Schlintl,Stefan Hecht,Hubert Hackl,Thomas Melchardt,Gabriel Rinnerthaler,Richard Greil,Lukas Weiss

Clinical Colorectal Cancer（2019）

引用 20|浏览22

暂无评分

摘要

The frequency of sarcopenia increases during the course of mCRC and negatively affects survival. In contrast to TAS-102, regorafenib is associated with increased skeletal muscle loss during mCRC treatment and should therefore be used with caution in mCRC patients with preexisting sarcopenia or a history of recent weight loss.

查看译文

关键词

Cross-sectional image,mCRC,Sarcopenia,Third-line therapy,Trifluridine/tipiracil

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要